Skip to Main Content

Paper Details

Dolutegravir Plus Lamivudine Maintains Human Immunodeficiency Virus-1 Suppression Through Week 48 in a Pilot Randomized Trial.
Clin Infect Dis
73
2018
Dolutegravir, Human Immunodeficiency Virus-1, Lamivudine
Author NameAffiliation
Vincent C MarconiEmory University School of Medicine
Carl J FichtenbaumUniversity of Cincinnati
Paul E SaxHarvard Medical School
  • 1 - 3

Datasets

Release 1.2